Cyclodestructive Procedures in Glaucoma: A Review of Current and Emerging Options
- PMID: 30448885
- PMCID: PMC6267695
- DOI: 10.1007/s12325-018-0837-3
Cyclodestructive Procedures in Glaucoma: A Review of Current and Emerging Options
Abstract
The first surgical modalities to reduce aqueous humor production by damaging the ciliary body date back to the early twentieth century. Until recently, however, cyclodestructive procedures (e.g., cyclocryotherapy and transscleral diode laser photocoagulation) have been reserved as last option procedures in refractory glaucoma patients with poor visual potential. Emerging technologic innovation has led to the development of promising, safer and less destructive techniques, such as micropulse diode cyclophotocoagulation, endoscopic cyclophotocoagulation and ultrasound cyclodestruction. Consequently, an emerging paradigm shift is under way with the selection of these surgical options in eyes with less severe glaucoma and good visual potential. Although existing evidence has not, as yet, adequately defined the role and value of these procedures, their emergence is a welcome expansion of available options for patients with moderate-to-severe glaucoma. This article reviews the pertinent evidence on both established and evolving cyclodestructive techniques and describes their growing role in the management of glaucoma.
Keywords: Cyclocryotherapy; Cyclodestruction; Cyclophotocoagulation; Diode laser; Endoscopic photocoagulation; High-intensity focused ultrasound; Micropulse diode; Ophthalmology; Refractory glaucoma; Ultrasound cyclodestruction.
Conflict of interest statement
Anna I. Dastiridou has nothing to disclose. Andreas Katsanos has received honoraria and congress expenses by Allergan, Novartis, Laboratoires Théa and Vianex. Philippe Denis has received lecture fees from Alcon, Allergan, EyeTechCare, Novartis, Santen and Laboratoires Théa. Brian A. Francis has received research support from BVI Endo Optiks and Iridex. Dimitrios G. Mikropoulos has received honoraria from Allergan, Novartis and Vianex. Miguel A. Teus has received lecture fees from Alcon, Allergan, Johnson & Johnson, Novartis; consultancy fees from Alcon, Allergan, Novartis; study & travel support from Alcon, Novartis and Johnson & Johnson. Anastasios-Georgios Konstas has received honoraria from Allergan, Bayer Healthcare, Mundipharma, Santen and Vianex; research funding from Allergan, Novartis and Santen.
Figures
References
-
- Shahan W, Post L. Thermophore studies in glaucoma. Am J Ophthalmol. 1921;4:109–18. 10.1016/S0002-9394(21)90829-8 - DOI
-
- Verhoeff F. Cyclectomy: a new operation for glaucoma. Arch Ophthalmol. 1924;53:228–9.
Publication types
MeSH terms
Associated data
LinkOut - more resources
Full Text Sources
Medical
